Myostatin inhibitors and the paradox of larger but weaker muscles
Key claim: Attia argues that myostatin inhibitors (new and old) can preserve or increase lean mass yet paradoxically fail to boost muscle strength.
Abstract
Drugs, new and old, that preserve lean mass, but fail to boost strength The post Myostatin inhibitors and the paradox of larger but weaker muscles appeared first on Peter Attia MD.
Why this matters
Myostatin inhibitors are a recurring longevity-clinic and biohacker interest because ‘more lean mass’ sounds like a direct answer to sarcopenia. Attia’s framing surfaces a divergence the trend tends to obscure: cross-trial, the drugs do enlarge muscle but fail to reliably increase strength — the outcome that actually tracks healthspan. The gap between the marketed proxy (mass) and the functional endpoint (strength) is the story.